The GI-MAP markers your standard
stool culture will never find.

You've had a stool test. Your GP sent a sample to the lab. It came back negative. No infection found. You still have bloating, alternating bowels, pain, and fatigue that have been present for years. You've been given an IBS diagnosis — meaning: we don't know what's causing this — and told to manage your diet and stress.

The problem is not that nothing is there. The problem is that the test you had is not capable of finding most of what causes the symptoms you're experiencing.

Standard stool culture: what it can and can't detect

Standard NHS stool culture grows bacteria on agar plates and identifies what colonies appear. This is a 19th-century technique that works well for acute bacterial infections — Salmonella, Campylobacter, E. coli O157. For these pathogens, it is reliable.

For everything else — parasites, viruses, most fungi, and the subtler bacterial dysbiosis patterns that drive chronic gut dysfunction — it is not. The sensitivity of standard stool culture for Blastocystis hominis, for example, is estimated at around 30%. For Giardia, somewhere between 50–70% depending on the technique used. For H. pylori, single-sample culture sensitivity is under 50%. For Cryptosporidium, standard culture is essentially useless.

The GI-MAP uses quantitative PCR — DNA-based testing that identifies organisms by their genetic material rather than by growing them in a dish. Sensitivity for the organisms above is above 95%. This is not a marginal improvement. It is a different category of test.

What the GI-MAP detects that standard culture misses

Blastocystis hominis

Blastocystis is one of the most common gut parasites in humans, present in an estimated 20–30% of the global population. It is predominantly transmitted through contaminated water and food. Standard stool culture misses it in the majority of cases. On the GI-MAP it appears routinely — often in clients who have had multiple negative standard stool tests and been told they have IBS.

The clinical significance of Blastocystis is debated — some carriers are asymptomatic, others present with significant IBS symptoms. The clinical judgment is contextual: high levels alongside elevated calprotectin, low secretory IgA, and significant gut symptoms warrant treatment. Low levels in an otherwise healthy microbiome may be tolerated. The point is that you cannot make that judgment if you don't know it's there.

Giardia duodenalis

Giardia colonises the small intestine and produces significant malabsorption — fat malabsorption, B12 depletion, and the characteristic bloating, flatulence, and pale greasy stools. It is consistently underdiagnosed by standard culture. Many clients with years of IBS-type symptoms who test negative on standard stool culture receive a positive Giardia result on PCR testing. Post-infectious IBS following Giardia is a well-documented entity — even after successful eradication, gut function may be disrupted for months.

H. pylori — including CagA virulence factors

H. pylori is present in approximately 50% of the global population. It colonises the gastric mucosa, reduces stomach acid, impairs iron and B12 absorption, and significantly elevates the risk of gastric ulcers and gastric cancer — particularly in CagA-positive strains.

The GI-MAP does not only detect H. pylori — it quantifies the load and identifies the CagA and VacA virulence factors. CagA-positive H. pylori represents the highest-risk clinical presentation. Standard stool antigen tests detect presence but not virulence status. The clinical priority of eradication changes significantly with a CagA-positive result.

What the GI-MAP measures beyond pathogens

Detection of organisms is only part of the GI-MAP picture. The test also assesses gut function and immune status in ways that standard investigation doesn't approach.

Secretory IgA (sIgA) — the primary immune defence of the gut mucosa. Low sIgA indicates depleted mucosal immunity, typically driven by chronic stress, overtraining, or steroid medication. A client with normal pathogen results but severely depleted sIgA has a gut that is vulnerable to infection and unable to mount an appropriate immune response to dietary antigens.

Pancreatic elastase — the most reliable non-invasive marker of exocrine pancreatic function. Below 200 µg/g indicates meaningful enzyme insufficiency. A client with low elastase may be eating an excellent diet and absorbing poorly — the food is not getting broken down into absorbable nutrients. This pattern — eating well, supplementing well, and still depleted — is the clinical picture of pancreatic enzyme insufficiency.

Calprotectin — the gold standard marker for intestinal inflammation. Above 200 µg/g, IBD must be ruled out. Below 50 µg/g indicates no significant mucosal inflammation. The number contextualises everything else on the panel.

Beta-glucuronidase — perhaps the most underappreciated marker on the GI-MAP. Elevated beta-glucuronidase indicates that gut bacteria are deconjugating processed oestrogen in the colon, allowing it to be reabsorbed rather than excreted. This drives oestrogen burden — PMS, breast tenderness, oestrogen dominance symptoms — through a gut mechanism that is invisible to standard hormone testing. Calcium D-glucarate blocks this process. But again, you need to know it's elevated before you can address it.

Standard stool culture is an appropriate tool for acute gastrointestinal illness. It is not an appropriate tool for investigating chronic gut dysfunction, persistent IBS symptoms, or the gut component of systemic presentations like fatigue, hormonal imbalance, or autoimmune conditions. The GI-MAP is a different instrument — and for those presentations, it is the right one.